The A498 cell line is a human cancer cell line derived from a patient with renal cell carcinoma (RCC), which is a type of kidney cancer. The A498 cell line is widely used in cancer research, particularly in studying the biology of renal cell carcinoma, drug resistance, and the development of novel therapeutics.
Researchers use the A498 cell line for various purposes, such as:
- Investigating the molecular mechanisms underlying renal cell carcinoma development and progression.
- Studying the cellular response to chemotherapeutic agents, targeted therapies, and immunotherapies, as well as developing strategies for overcoming drug resistance.
- Evaluating the efficacy of novel anticancer therapeutics and treatment strategies in vitro before testing them in in vivo models.
- Identifying and validating potential therapeutic targets and biomarkers for renal cell carcinoma.
Using the A498 cell line, along with other renal cell carcinoma cell lines, has contributed to the advancement of knowledge in the field of kidney cancer research and has helped in the development of more effective treatment options for patients.